Trial Profile
A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2019
Price :
$35
*
At a glance
- Drugs L-DOS 47 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Helix BioPharma
- 25 Oct 2019 According to a Helix BioPharma media release, all analyses have been completed for this study and a draft clinical study report is currently under review and expected to be finalized by the end of calendar 2019.
- 19 Mar 2018 According to a Helix BioPharma media release, this study was terminated due to lack of efficacy and the company is currently awaiting the finalized reports.
- 05 Jan 2018 According to a Helix BioPharma media release, as per the Trial Steering Committee's recommendation, the Company has decided not to continue with this study.